Work

Tirabrutinib-associated toxic epidermal necrolysis: a case report and review of the literature

Year: 2025

Type: article

Abstract: Tirabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, has shown efficacy in recurrent or refractory diffuse large B-cell lymphoma (DLBCL). However, severe drug eruptions, including toxic epidermal necrolysis (TEN), have been reported. We present a case of a 74-year-old man with refractory DLBCL who developed TEN after 1 month of tirabrutinib treatment. Severe drug eruptions linked to tirabrutinib are rare, with only three cases reported, including ours. Tirabrutinib’s selective BTK inhibition may activate cytotoxic CD8+ T cells, contributing to Stevens–Johnson syndrome/TEN pathogenesis. Further studies are needed to clarify the mechanisms and develop better diagnostic approaches for BTK inhibitor-related drug eruptions.

Source: Skin Health and Disease

DOI: 10.1093/skinhd/vzaf011

Authors: Noriko Ikegawa, Natsuko Saito-Sasaki, Yu Sawada

Institution: University of Occupational and Environmental Health Japan

Language: English

Topic: Drug-Induced Adverse Reactions

Subfield: Pharmacology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,597